Rhenman & Partners Asset Management’s AstraZeneca AZN Stock Holding History

Rhenman & Partners Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.5M	Buy	+151,500	New	+$28.5M	2.69%	3

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Rhenman & Partners Asset Management's AZN Position: Q2 2026 in Review

Rhenman & Partners Asset Management opened a new position in AstraZeneca (AZN) in Q2 2026: 151,500 shares worth $28.5M. The stake represents 2.69% of the portfolio and ranks #3 among its holdings.

1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Rhenman & Partners Asset Management held 151,500 shares of AstraZeneca worth $28.5M as of Q2 2026.
AstraZeneca was a new Rhenman & Partners Asset Management position in Q2 2026.
AstraZeneca made up 2.69% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #3 holding.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.